hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06333223 id: LSC 23/ 396 briefTitle: Polyphenols and Probiotics to Improve Menopausal Symptoms Via the Gut-Brain Axis acronym: SYMPTOGUT overallStatus: RECRUITING date: 2024-03-18 date: 2024-12-18 date: 2025-03-30 date: 2024-03-27 date: 2024-03-29 name: University of Roehampton class: OTHER name: King's College briefSummary: Menopause is one of the most significant lifecourse challenges for women. The decline in female sex hormones, in particular estrogen, during menopause leads to an increased risk in cardiometabolic diseases, and a decrease in quality of life due to symptoms such as low mood, anxiety, hot flushes and difficulty sleeping. As life expectancy continues to increase, on average, women will spend one third of their life in the postmenopausal period. Increasing evidence suggests that the gut microbiota plays a key role in menopause-related symptoms and conditions, being one of the main regulators of circulating sex hormones. Menopause has been linked to gut dysbiosis and lower gut microbial diversity, therefore nutritional strategies targeting the gut microbiome may be an effective approach to improve women's health during menopause. Both (poly)phenols and probiotics are promising candidates for the prevention and treatment of menopausal symptoms via different mechanisms, including the modulation of the gut-brain axis, while emerging evidence indicates that using both together may be a better approach than traditional carbohydrate-based synbiotics.
To our knowledge, the efficacy of a (poly)phenol based synbiotic targeting the gut microbiome for improvement of menopausal symptoms has not been investigated so far. conditions: Menopause studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Arm 1: Mixture of (Poly)phenols and a probiotic supplement Arm 2: (Poly)phenols and maltodextrin (placebo) primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Mixture of (Poly)phenols and a probiotic supplement name: Placebo comparator measure: Change in blood chemistry levels measure: Change in BMI (body mass index) Scores measure: Change in the gut microbiota diversity measure: Change in dietary habits measure: Change in Quality IPAQ measure: Change in inflammatory biomarkes sex: FEMALE minimumAge: 48 Years maximumAge: 60 Years stdAges: ADULT facility: Health Sciences Research Centre, Life Sciences Department, University of Roehampton status: RECRUITING city: London state: UK zip: SW15 4JD country: United Kingdom name: Adele Costabile role: CONTACT lat: 51.50853 lon: -0.12574 facility: Adele Costabile status: RECRUITING city: London zip: SW145JD country: United Kingdom name: Adele Costabile, Prof role: CONTACT name: Zicheng Zhang role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06333197 id: Mandibular condylar fracture briefTitle: Approaches for Open Reduction and Internal Fixation of Mandibular Condylar Fracture overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03-01 date: 2025-07-01 date: 2024-03-27 date: 2024-03-28 name: Assiut University class: OTHER briefSummary: The condylar region is the most frequent anatomical site for mandibular fractures .
Condylar fractures constitute 25.5% to 35.5% of all mandibular fractures. The mandibular condyle fracture is a type of fracture that affects the condyle, which is the knuckle-like projection of the mandible (lower jaw) that articulates with the temporal bone to form the temporomandibular joint (TMJ). conditions: Mandibular Fractures studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: ALL Patients diagnosed with Extra Capsular Fracture of Mandibular Condyle amenable for surgery. primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: ORIF through transparotid approach name: ORIF through retroparotid approach measure: Facial nerve injury measure: Operative time measure: Fracture stability measure: Mouth opening measure: Other Complication related to the Approach sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333184 id: 3085-4215 briefTitle: Smoothies and Blood Sugars overallStatus: RECRUITING date: 2024-03-20 date: 2024-08-31 date: 2024-12-31 date: 2024-03-27 date: 2024-03-27 name: University of Bath class: OTHER briefSummary: Glycaemic responses to fruit smoothies may depend on the food matrix (e.g., degree of processing and physical structure), ingestion rate, dose ingested and fibre content. Furthermore, the method of sampling could alter inferences. The aim of this project is to characterise how these factors affect the glycaemic response to a commercially available fruit smoothie. Participants will ingest 7 different test drinks in a randomised, crossover design with fingerstick capillary blood sampling alongside continuous glucose monitors. Test drinks will include a glucose reference (CONTROL), the commercial product matched for carbohydrate to CONTROL (PRODUCT), equivalent carbohydrate ingested as whole fruits (WHOLE), equivalent carbohydrate ingested as blended fruits (WHOLE), equivalent carbohydrate as the commercial product ingested slowly (SLOW), equivalent carbohydrate as the commercial product ingested with additional fibre (FIBRE), and the commercial product ingested in a dose typically bought (DOSE). These data will provide insight into how the food matrix and different patterns of ingestion can alter the glycaemic response to a fruit smoothie, and how the measurement method may alter interpretations. conditions: Metabolic Disturbance studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: NONE count: 15 type: ESTIMATED name: Food measure: Glycaemic index of product with capillary vs CGM measure: Glycaemic index of all conditions with capillary vs CGM measure: Condition-by-sampling interaction measure: GI of products in capillary samples measure: GI of products in continuous glucose monitors measure: Peak glucose capillary vs CGM measure: Time to peak glucose capillary vs CGM sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department for Health, University of Bath status: RECRUITING city: Bath zip: BA2 7AY country: United Kingdom name: Javier T Gonzalez, PhD role: CONTACT phone: +44 (0) 1225 38 phoneExt: 5125 email: j.t.gonzalez@bath.ac.uk lat: 51.3751 lon: -2.36172 hasResults: False
nctId: NCT06333171 id: 00003872 briefTitle: 4-aminopyridine for Skin Wound Healing overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2027-09 date: 2028-03 date: 2024-03-27 date: 2024-03-27 name: John Elfar class: OTHER briefSummary: Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.
The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing. conditions: Wounds conditions: Wound of Skin conditions: Wound Heal conditions: Wounds and Injuries studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a double-blind, randomized, placebo-controlled trial design. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Subjects in both aims will be assigned to Group A or Group B using a randomization scheme. Each study participant for each aim is randomly assigned to either treatment of placebo using permuted block randomization whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 68 type: ESTIMATED name: 4-Aminopyridine name: Placebo measure: Return of skin integrity and wound closure after skin punch biopsy measure: The effect of 4-AP on the hair number and growth at the skin punch biopsy site. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Arizona city: Tucson state: Arizona zip: 85724 country: United States name: Andrea Horne role: CONTACT phone: 520-626-6456 email: ahh@arizona.edu lat: 32.22174 lon: -110.92648 hasResults: False
nctId: NCT06333158 id: AmWaRO Study briefTitle: Extracts of Amla, Walnut Leaf, Red Yeast Rice and Olive in Cardiovascular Prevention acronym: AmWaRO overallStatus: RECRUITING date: 2024-03-01 date: 2024-09 date: 2024-12 date: 2024-03-27 date: 2024-03-27 name: Nina Hermans class: OTHER name: University Hospital, Antwerp briefSummary: The aim of this study is to evaluate whether the use of a commercially available standardized combination preparation (Cholesfytol NG®), containing extracts of amla, walnut leaf, red yeast rice and olive, in individuals with hypercholesterolemia
* Placebo All treatments have an identical shape and color and should be used in the same way (oral intake; 3 capsules/day during dinner). No dietary instructions are given and participants are asked not to change their dietary habits, not to start other therapies (medication, supplements, slimming diets, extra physical activity, etc.) during their study period. Standardized questionnaires are used to obtain information on demographics, dietary habits and side effects. At baseline and after 8 weeks, 27 ml blood is drawn for various biological analyses, and blood pressure, BMI and waist circumference are measured. conditions: Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: Cholesfytol NG name: Placebo measure: Change from baseline LDL cholesterol at 8 weeks measure: Frequency of side effects (+ their burden) as reported in the final questionnaire measure: Change from baseline Blood Pressure, Systolic at 8 weeks measure: Change from baseline Blood Pressure, diastolic at 8 weeks measure: Change from baseline total cholesterol level at 8 weeks measure: Change from baseline HDL cholesterol level at 8 weeks measure: Change from baseline non-HDL cholesterol level at 8 weeks measure: Change from baseline Remnant Cholesterol at 8 weeks measure: Change from baseline triglycerides level at 8 weeks measure: Change from baseline Apo A1 level at 8 weeks measure: Change from baseline Apo B level at 8 weeks measure: Change from baseline lipoprotein A (LP(a)) level at 8 weeks measure: Change from baseline OxLDL level at 8 weeks measure: Change from baseline malondialdehyde (MDA) level at 8 weeks measure: Change from baseline glutathion (GSH) level at 8 weeks measure: Change from baseline glucose level at 8 weeks measure: Change from baseline HbA1c level at 8 weeks measure: Change from baseline insuline level at 8 weeks measure: Change from baseline Body Mass Index (BMI) at 8 weeks measure: Change from baseline waist circumference at 8 weeks measure: Change from baseline hemoglobine level at 8 weeks measure: Change from baseline creatinine level at 8 weeks measure: Change from baseline hs-CRP level at 8 weeks measure: Change from baseline homocysteine level at 8 weeks measure: Change from baseline creatine kinase (CK) level at 8 weeks measure: Change from baseline C-peptide level at 8 weeks sex: ALL minimumAge: 18 Years maximumAge: 76 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UAntwerp, NatuRAPT status: RECRUITING city: Wilrijk state: Antwerp zip: 2610 country: Belgium name: Nina Hermans, Prof. role: CONTACT phone: 003232652732 email: nina.hermans@uantwerpen.be lat: 51.16734 lon: 4.39513 hasResults: False
nctId: NCT06333145 id: EDRA briefTitle: ED90 of Remimazolam Anesthesia Induction in Drug-induced Sleep Endoscopy in Adults overallStatus: RECRUITING date: 2024-02-04 date: 2024-12-31 date: 2024-12-31 date: 2024-03-27 date: 2024-03-27 name: Tongji Hospital class: OTHER briefSummary: Exploring the ED90 of remimazolam in Drug-induced Sleep Endoscopy in adults at different BMI groups. conditions: Effect of Drug studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 110 type: ESTIMATED name: Remimazolam measure: Ramsey Sedation Scale measure: Time records measure: Use of drugs measure: Respiratory suppression incidence measure: Incidence of Treatment-Emergent Adverse Events measure: Incidence of PACU Adverse Reactions sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji Hospital status: RECRUITING city: Wuhan state: Hubei zip: 430000 country: China name: aijun xu, Dr. role: CONTACT phone: 027-83663173 email: ajxu@tjh.tjmu.edu.cn name: yuan Bi, Dr. role: CONTACT phone: 027-18972718216 email: 18972718216@163.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06333132 id: DiabEAT.it briefTitle: Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat) acronym: DiabEATit overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2025-09-01 date: 2026-02-01 date: 2024-03-27 date: 2024-03-27 name: Azienda Ospedaliero, Universitaria Pisana class: OTHER briefSummary: The goal of this mechanistic study is to investigate the role of incretin hormones on weight loss-induced type 2 diabetes remission. conditions: Obesity conditions: Diabetes Mellitus Type 2 in Obese studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Weight loss-induced Diabetes Remission measure: Number of participants with incretin effect's restoration after achieving weightloss-induced diabetes remission measure: Rate of sustained weightloss-induced diabetes remission assessed by 2 consecutive HbA1c <48mmol/mol within 6 months sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliero-Universitaria Pisana city: Pisa state: PI zip: 56127 country: Italy lat: 43.70853 lon: 10.4036 hasResults: False
nctId: NCT06333119 id: 72867572-050.01.04-320 briefTitle: The Relationship Between Urinary Incontinence and Motor Symptoms overallStatus: COMPLETED date: 2023-09-01 date: 2024-01-31 date: 2024-02-15 date: 2024-03-27 date: 2024-03-27 name: Pinar Yasar class: OTHER briefSummary: There is no study in the literature examining the relationship between urinary incontinence and motor symptoms in individuals with stroke. The aim of this study is to determine the relationship between urinary incontinence and spasticity, balance and walking, which negatively affect quality of life and functional performance after stroke. conditions: Stroke conditions: Urinary Incontinence conditions: Motor Skills Disorders studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 46 type: ACTUAL name: modified rankin scale measure: relationship with between urinary incontinence and motor symptoms sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Suleyman Demirel University city: Isparta country: Turkey lat: 37.76444 lon: 30.55222 hasResults: False
nctId: NCT06333106 id: FICUS - 2024/16FEV/077 briefTitle: PoCUS Diagnostic Accuracy for Fecal Impaction in the Emergency Department: A Prospective Study overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-27 date: 2024-04-29 name: Cliniques universitaires Saint-Luc- Université Catholique de Louvain class: OTHER name: Université de Liège name: Grand Hôpital de Charleroi name: Clinique Saint-Jean, Bruxelles name: Clinique Saint Pierre Ottignies briefSummary: Many medical and paramedical specialties regularly use point-of-care ultrasound (PoCUS) in clinical practice. The diagnosis of fecal impaction is quite common in the elderly living in nursing homes with a prevalence of 47.3%. Fecal impaction remains a major source of morbidity, while its etiology is often multifactorial and its diagnosis challenging. Current recommendations for the diagnosis of fecal impaction support the use of plain abdominal x-rays. PoCUS is a non-irradiating procedure and a clinical diagnostic tool that can be used in a variety of ways during abdominal examinations. Most scientific societies encourage the use of PoCUS to respond to a specific clinical question rather than to provide a diagnosis, which is usually confirmed by conventional ultrasound. However, the combination of physical examination and PoCUS may improve the diagnostic approach. This multicentric prospective study protocol aims to evaluate the diagnostic accuracy of PoCUS in patients aged 75 years or older with suspected fecal impaction in the emergency department compared with plain abdominal x-ray (or abdominal CT scan if required as part of the emergency department investigations). conditions: Fecal Impaction of Colon studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 247 type: ESTIMATED name: POCUS diagnostic value measure: Evaluation of the diagnostic value of clinical ultrasound in the diagnosis of fecal impaction in the emergency room measure: Influence of BMI on the diagnosis of fecal impaction at PoCUS measure: Influence of bladder repletion on the diagnosis of fecal impaction using PoCUS measure: Influence of patient echogenicity on the diagnosis of fecal impaction using PoCUS sex: ALL minimumAge: 75 Years maximumAge: 130 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333093 id: NL82178.018.22 briefTitle: Duodenal tIssue ResEction aCquisiTion (DIRECT) Study acronym: DIRECT overallStatus: RECRUITING date: 2023-01-10 date: 2024-06-01 date: 2024-06-01 date: 2024-03-27 date: 2024-03-27 name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) class: OTHER briefSummary: To evaluate the quality of cold snare resection specimens of duodenal mucosa tissue in patients undergoing an upper gastrointestinal interventional endoscopy in order to improve the processing of histological samples and its assessment in general and for future duodenal ablation studies. conditions: Duodenum Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: Cold snare measure: Acquiring larger pieces of tissue from the duodenum measure: Histopatholocial assessment of larger pieces of tissue from the duodenum measure: Checking if the tissue is of good quality enough for single cell RNA sequencing sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Amsterdam UMC status: RECRUITING city: Amsterdam state: North-Holland zip: 1105 AZ country: Netherlands name: Celine BE Busch, MD role: CONTACT phone: +31621357593 email: diabetes-onderzoek@amsterdamumc.nl name: Jacques JG Bergman, MD PhD role: PRINCIPAL_INVESTIGATOR name: Celine BE Busch, MD role: SUB_INVESTIGATOR lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06333080 id: N-20220017 briefTitle: The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin acronym: DIACRON overallStatus: RECRUITING date: 2024-05-01 date: 2025-03 date: 2025-03 date: 2024-03-27 date: 2024-03-27 name: Aalborg University Hospital class: OTHER briefSummary: The objective of the trial is to investigate the effect of adherence to oral semaglutide dosing instructions on glycaemic control in people with type 2 diabetes, which are dysregulated on metformin and naïve to second line antidiabetic treatment. conditions: Diabetes Mellitus, Type 2 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED measure: Time-in-Range (TIR) measure: Pre-dose Fasting measure: Post-dose Fasting measure: Occurrence of nausea or vomiting measure: Water Intake at Dosing Time measure: Treatment-Related Impact Measure for Diabetes (TRIM-D) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Steno Diabetes Center North Denmark status: RECRUITING city: Aalborg zip: 9000 country: Denmark name: Mette Pilegaard Rasmussen, BSc role: CONTACT phone: 00 45 30 36 46 84 email: mpr@rn.dk name: Peter Vestergaard, MD role: PRINCIPAL_INVESTIGATOR name: Nynne S Holdt-Caspersen, MSc role: SUB_INVESTIGATOR lat: 57.048 lon: 9.9187 hasResults: False
nctId: NCT06333067 id: Sofwave21 briefTitle: Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators overallStatus: RECRUITING date: 2023-10-11 date: 2024-10-01 date: 2024-11-01 date: 2024-03-27 date: 2024-03-27 name: Sofwave Medical LTD class: INDUSTRY briefSummary: Open-label, non-randomized single-arm prospective, multi-center, self-controlled clinical study with masked evaluation. conditions: Lax Skin studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Sofwave measure: Primary Outcome Measure sex: ALL minimumAge: 35 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Costal Skin & Eye Institute status: RECRUITING city: La Mesa state: California zip: 91942 country: United States name: Christopher V.Crosby, MD role: CONTACT email: research@coastalskineye.com name: Christopher V.Crosby, MD role: PRINCIPAL_INVESTIGATOR lat: 32.76783 lon: -117.02308 facility: Skin Wellness Dermatology Associates status: RECRUITING city: Durham state: North Carolina zip: 27713 country: United States name: Talasia Smith role: CONTACT phone: 919-294-9440 email: cst@skinwellnessdermatology.com name: Brooke Jackson, MD role: PRINCIPAL_INVESTIGATOR lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06333054 id: NCLIN0091/ 14ct/mp37li briefTitle: Safety and Efficacy of a Head Lice Shampoo overallStatus: COMPLETED date: 2014-10-13 date: 2015-06-08 date: 2015-06-08 date: 2024-03-27 date: 2024-03-27 name: Oystershell NV class: INDUSTRY briefSummary: This study is designed to compare the effectiveness and safety of test head lice shampoo (Test product) versus Goldgeist® Forte (reference product) following two applications. conditions: Head Lice studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 109 type: ACTUAL name: Pyrethrum Extract name: Silcap Shampoo measure: Cure Rate superior to 70% for the test product measure: Cure Rate superior to 70% for the reference product measure: Superior cure rate to the reference measure: Non-inferiority rate to the reference measure: Local tolerability measure: Global tolerability measure: Skin irritation assessment measure: Eye irritation assessment measure: Esthetical effect of the anti-lice products measure: Adverse Events (AEs) measure: Severity of the lice infestation sex: ALL minimumAge: 1 Year stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: CardioSec Clinical Research GmbH city: Erfurt zip: 99084 country: Germany lat: 50.9787 lon: 11.03283 hasResults: False
nctId: NCT06333041 id: 32977-01-00 briefTitle: Study of Cannabidiol in Sanfilippo Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-01 date: 2027-05 date: 2024-03-27 date: 2024-04-19 name: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center class: OTHER briefSummary: The goal of this clinical trial is to test cannabidiol in Sanfilippo syndrome. The main questions it aims to answer are: 1) determine the safety of cannabidiol in Sanfilippo syndrome, and 2) explore the efficacy of cannabidiol in treating the neurobehavioral symptoms and functional outcomes of Sanfilippo syndrome.